[Pharmacokinetics in liver cirrhosis].
In patients with severe hepatic parenchymal damage drug metabolism is presumably impaired. The reduced detoxification can not be sufficiently described in the postulated multicompartment model by determination of plasma half-life, because it depends on the physicochemical properties of the drugs. An increase of dihydroxybilic acids inhibits drug metabolism. Some drugs and also its metabolites formed in the liver induce hepatic cell injury including necrosis and therefore they are contraindicated in patients suffering from liver disease.
D000632:Aminopyrine / Q000378:metabolism; D001711:Biotransformation; D002701:Chloramphenicol / Q000378:metabolism; D003374:Coumarins / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008103:Liver Cirrhosis / Q000378:metabolism*; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010653:Phenylbutazone / Q000378:metabolism; D012459:Salicylates / Q000378:metabolism; D014044:Tolbutamide / Q000378:metabolism
D003374:Coumarins; D004364:Pharmaceutical Preparations; D012459:Salicylates; D000632:Aminopyrine; D002701:Chloramphenicol; D014044:Tolbutamide; D010653:Phenylbutazone
Pharmakokinetik bei Leberzirrhose